ArticlePloS one2017
Molecular subtyping of Treponema pallidum and associated factors of serofast status in early syphilis patients: Identified novel genotype and cytokine marker.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Risk factors of serofast state in patients undergoing syphilis: a meta-analysis of 17 cohort studies.Frontiers in immunology · 2025Pooled it
- Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Cytotoxic T-cell deficiency and sustained B-cell activation in serofast syphilis: a prospective observational study.Frontiers in immunology · 2026Observational
- Analysis of influencing factors for syphilis serofast and development and evaluation of a predictive model.Frontiers in immunology · 2026Article
- Neurosyphilis: insights into its pathogenesis, susceptibility, diagnosis, treatment, and prevention.Frontiers in neurology · 2023Review
- Brazilian Protocol for Sexually Transmitted Infections 2020: acquired syphilis.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Bioinformatics analysis of genes related to iron death in diabetic nephropathy through network and pathway levels based approaches.PloS one · 2021Article
- Predictors of serofast state after treatment of patients with syphilis.Chinese medical journal · 2020Article
- Molecular Characterization Based on MLST and ECDC Typing Schemes and Antibiotic Resistance Analyses ofFrontiers in cellular and infection microbiology · 2020Article
- Is repeated retreatment necessary for HIV-negative serofast early syphilis patients?Experimental and therapeutic medicine · 2020Article
- Early syphilis: risk factors and clinical manifestations focusing on HIV-positive patients.BMC infectious diseases · 2019Article
- Cytokine expression in Treponema pallidum infection.Journal of translational medicine · 2019Article
- Article
- Article
- Article
- Development of a Multilocus Sequence Typing (MLST) scheme for Treponema pallidum subsp. pertenue: Application to yaws in Lihir Island, Papua New Guinea.PLoS neglected tropical diseases · 2017Article
- Predictors of serological cure and serofast stage after treatment in patients with syphilis: A retrospective study from India.Indian journal of sexually transmitted diseases and AIDSArticle
- Acquired syphilis: update on clinical, diagnostic and therapeutic aspectsAnais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serofast, a persistent nontreponemal serological response observed in early syphilis patients after conventional treatment, remains a concern of clinicians and syphilis patients. No consensus has been established, however, that defines an effective treatment strategy and clarifies the pathogenesis. In this study, 517 patients with early syphilis were enrolled and treated. Twelve months after treatment, 79.3% (410/517) of patients achieved serological cure, 20.1% (104/517) were serofast, and 0.6% (3/517) were serological failures. Multivariate analysis demonstrated that older age (>40 years) and lower baseline RPR titer (≤ 1:8) were associated with serofast status. We also identified 21 T. pallidum molecular subtypes among early syphilis patients and detected a new subtype, 14i/a. We found that the proportion of 14i/a type in serofast patients was significantly higher than that in patients with serological cure, predicting an increasing risk of serofast status. Levels of chemerin were higher in the serum of serofast cases than serological cure cases, potentially indicating a novel cytokine marker for serofast in early syphilis patients after therapy. We hope that these results contribute to improve guidelines for the management of syphilis patients who experience serofast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.